Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bernd Stratmann has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nitro-oleic acid enhances mitochondrial metabolism and ameliorates heart failure with preserved ejection fraction in mice

    by Marion Müller, Torben Schubert, Cornelius Welke, Tibor Maske, Thomas Patschkowski, Elfi Donhauser, Jacqueline Heinen-Weiler, Felix-Levin Hormann, Sven Heiles, Tina Johanna Schulz, et al.

    The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing, while treatment options are inadequate. Hypertension and obesity-related metabolic dysfunction contribute to HFpEF. Nitro-oleic acid (NO2-OA) impacts metabolic syndromes by improving glucose tolerance and adipocyte function. Here we show that treatment with NO2-OA ameliorates diastolic dysfunction and heart failure symptoms in a HFpEF mouse model induced by high-fat diet and inhibition of the endothelial nitric oxide synthase. Proteomic analysis of left ventricular tissue reveals that one-third of identified proteins, predominantly mitochondrial, are upregulated in hearts of NO2-OA-treated HFpEF mice compared to naïve and vehicle-treated HFpEF mice. Increased mitochondrial mass and numbers, and enhanced mitochondrial respiration are linked with this response, as assessed by transmission electron microscopy and high-resolution respirometry. Activation of the 5’-adenosine-monophosphate-activated-protein-kinase (AMPK) signaling pathway mediates the enhancement of mitochondrial dynamics in hearts of NO2-OA-treated HFpEF mice. These findings suggest that targeting mitochondrial function with NO2-OA may represent a promising therapeutic strategy for HFpEF.


  • Open Access

    IAPP - oligomerisation levels in plasma of people with type 2 diabetes

    by Fabian Rehn, Victoria Kraemer-Schulien, Tuyen Bujnicki, Oliver Bannach, Diethelm Tschoepe, Bernd Stratmann, Dieter Willbold

    Islet amyloid polypeptide (IAPP) is co-secreted with insulin from pancreatic ß-cells. Its oligomerisation is regarded as disease driving force in type 2 diabetes (T2D) pathology. Up to now, IAPP oligomers have been detected in affected tissues. IAPP oligomer concentrations in blood have not been analysed so far. Using the IAPP single-oligomer-sensitive and monomer-insensitive surface-based fluorescence intensity distribution analysis (sFIDA) technology, levels of IAPP oligomers in blood plasma from healthy controls and people with T2D in different disease stages where determined. Subsequently, the level of IAPP oligomerisation was introduced as the ratio between the IAPP oligomers determined with sFIDA and the total IAPP concentration determined with ELISA. Highest oligomerisation levels were detected in plasma of people with T2D without late complication and without insulin therapy. Their levels stand out significantly from the control group. Healthy controls presented with the lowest oligomerisation levels in plasma. In people with T2D without complications, IAPP oligomerisation levels correlated with disease duration. The results clearly demonstrate that IAPP oligomerisation in insulin-naïve patients correlates with duration of T2D. Although a correlation per se does not identify, which is cause and what is consequence, this result supports the hypothesis that IAPP aggregation is the driving factor of T2D development and progression. The alternative and conventional hypothesis explains development of T2D with increasing insulin resistance causing exhaustion of pancreatic ß-cells due to over-secretion of insulin, and thus IAPP, too, resulting in subsequent IAPP aggregation and fibril deposition in the pancreas. Further experiments and comparative analyses with primary tissues are warranted.


  • Open Access

    Maladaptive response following glucose overload in GLUT4 ‐overexpressing H9C2 cardiomyoblasts

    by Bernd Stratmann, Britta Eggers, Yvonne Mattern, Tayana Silva de Carvalho, Katrin Marcus‐Alic, Diethelm Tschoepe

    Background: Glucose overload drives diabetic cardiomyopathy by affecting the tricarboxylic acid pathway. However, it is still unknown how cells could overcome massive chronic glucose influx on cellular and structural level. Methods/Materials: Expression profiles of hyperglycemic, glucose transporter‐4 (GLUT4) overexpressing H9C2 (KE2) cardiomyoblasts loaded with 30 mM glucose (KE230L) and wild type (WT) cardiomyoblasts loaded with 30 mM glucose (WT30L) were compared using proteomics, real‐time polymerase quantitative chain reaction analysis, or Western blotting, and immunocytochemistry. Results: The findings suggest that hyperglycemic insulin‐sensitive cells at the onset of diabetic cardiomyopathy present complex changes in levels of structural cell‐related proteins like tissue inhibitor of metalloproteases‐1 (1.3 fold), intercellular adhesion molecule 1 (1.8 fold), type‐IV‐collagen (3.2 fold), chaperones (Glucose‐Regulated Protein 78: 1.8 fold), autophagy (Autophagosome Proteins LC3A, LC3B: 1.3 fold), and in unfolded protein response (UPR; activating transcription factor 6α expression: 2.3 fold and processing: 2.4 fold). Increased f‐actin levels were detectable with glucose overload by immnocytochemistry. Effects on energy balance (1.6 fold), sirtuin expression profile (Sirtuin 1: 0.7 fold, sirtuin 3: 1.9 fold, and sirtuin 6: 4.2 fold), and antioxidant enzymes (Catalase: 0.8 fold and Superoxide dismutase 2: 1.5 fold) were detected. Conclusion: In conclusion, these findings implicate induction of chronic cell distress by sustained glucose accumulation with a non‐compensatory repair reaction not preventing final cell death. This might explain the chronic long lasting pathogenesis observed in developing heart failure in diabetes mellitus.


  • Multimodale Wundbehandlung bei diabetischem Fußsyndrom mit Osteomyelitis

    by Tatjana Opacic, Abdulwahab Arbi, Bernd Stratmann, Diethelm Tschöpe

    Osteomyelitis in Zusammenhang mit dem Diabetisches Fußsyndrom stellt in der derzeitigen klinischen Praxis ein komplexes Problem dar. Nach angiologischer Intervention wird oftmals ein chirurgischer Eingriff empfohlen. Ein möglicher Abheilungsversuch unter konservativem Procedere mit Gliedmaßenerhalt wird somit oftmals umgangen, was die Zahl von Major-Amputationen erhöht. Im unseren Wundheilzentrum steht die multimodale adjuvante Wundbehandlung im Vordergrund. Neben leitliniengerechter angiologischer Revaskularisation und chirurgischen Eingriffen sind adjuvante Verfahren inklusive Vakuum- und Prostaglandintherapie, sowie der Einsatz von Kaltplasma, verschiedenen Wundauflagen und Wachstumsfaktoren (Platelet-Rich-Fibrin (PRF)) möglich. Hier berichten wir über vier männliche Patienten im Alter vom 79.5±7.4 Jahren, die eine Wunde mit Knochenkontakt (7±2 cm x 5,0±1,4 cm) hatten. Initial erfolgte ein chirurgischer Eingriff (chirurgisches Debridement, Digitus- oder MFK-Amputation), gefolgt mit einem oder zwei Zyklen lokaler Vakuumtherapie. Anschließend erfolgte die Therapie mittels PRF sowie in einem Fall zusätzlich die Applikation von Extrazellularmatrix. Drei Patienten hatten eine interventionswürdige pAVK von Unterschenkeltyp, die vor der Wundbehandlung durch perkutane transluminale Angioplastie (PTA) behandelt wurde (bei zwei von drei Patienten 2 bzw. 5 Jahre vorher, bei einem Patienten unmittelbar vorher). Danach wurden die Patienten mit adäquatem Wundverband in die ambulante Betreuung durch Hausarzt bzw. ambulanten Pflegedienst entlassen. Die Patienten waren im regelmäßigen Abstanden in unserem Wundheilzentrum vorstellig. Bei drei von vier Patienten wurde eine komplette Abheilung innerhalb vom 206±72 Tagen beobachtet. Das hier vorgestellte Prozedere führte im Teil der Fälle zur kompletten Abheilung. In Übereinstimmung mit den Leitlinien ist somit durch Individualisierung und multimodale Verfahren Wundheilung auch in komplexen Fällen unter Knochenbeteiligung möglich. Article published online: 02 May 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Mosaic vs. Single Image Analysis with Confocal Microscopy of the Corneal Nerve Plexus for Diagnosis of Early Diabetic Peripheral Neuropathy

    by Aleksandra Matuszewska-Iwanicka, Bernd Stratmann, Oliver Stachs, Stephan Allgeier, Andreas Bartschat, Karsten Winter, Rudolf Guthoff, Diethelm Tschoepe, Hans-Joachim Hettlich

    Introduction The assessment of the corneal nerve fibre plexus with corneal confocal microscopy (CCM) is an upcoming but still experimental method in the diagnosis of early stage diabetic peripheral neuropathy (DPN). Using an innovative imaging technique—Heidelberg Retina Tomograph equipped with the Rostock Cornea Module (HRT-RCM) and EyeGuidance module (EG)—we were able to look at greater areas of subbasal nerve plexus (SNP) in order to increase the diagnostic accuracy. The aim of our study was to evaluate the usefulness of EG instead of single image analysis in diagnosis of early stage DPN. Methods This prospective study was performed on 60 patients with type 2 diabetes mellitus, classified equally into two subgroups based on neuropathy deficient score (NDS): patients without DPN (group 1) or with mild DPN (group 2). The following parameters were analysed in the two subgroups: corneal nerve fibre length (CNFL; mm/mm2), corneal nerve fibre density (CNFD; no./mm2), corneal nerve branch density (CNBD; no./mm2). Furthermore, we compared the data calculated with the novel mosaic, EG-based method with those received from single image analysis using different quantification tools. Results Using EG we did not find a significant difference between group 1 and group 2: CNFL (16.81 ± 5.87 mm/mm2 vs. 17.19 ± 7.19 mm/mm2, p = 0.895), CNFD (254.05 ± 115.36 no./mm2 vs. 265.91 ± 161.63 no./mm2, p = 0.732) and CNBD (102.68 ± 62.28 no./mm2 vs. 115.38 ± 96.91 no./mm2, p = 0.541). No significant difference between the EG method of analysing the SNP and the single image analysis of 10 images per patient was detected. Conclusion On the basis of our results it was not possible to differentiate between early stages of large nerve fibre DPN in patients with type 2 diabetes mellitus via SNP analysis. To improve sensitivity and specificity of this method newer technologies are under current evaluation. Trial Registration ClinicalTrials.gov Identifier NCT05326958.


  • Open Access

    Chronic Hyperglycaemia Inhibits Tricarboxylic Acid Cycle in Rat Cardiomyoblasts Overexpressing Glucose Transporter Type 4

    by Bernd Stratmann, Britta Eggers, Yvonne Mattern, Tayana Silva de Carvalho, Katrin Marcus, Diethelm Tschoepe

    An oversupply of nutrients with a loss of metabolic flexibility and subsequent cardiac dysfunction are hallmarks of diabetic cardiomyopathy. Even if excess substrate is offered, the heart suffers energy depletion as metabolic fluxes are diminished. To study the effects of a high glucose supply, a stably glucose transporter type 4 (GLUT4)-overexpressing cell line presenting an onset of diabetic cardiomyopathy-like phenotype was established. Long-term hyperglycaemia effects were analysed. Rat cardiomyoblasts overexpressing GLUT4 (H9C2KE2) were cultured under normo- and hyperglycaemic conditions for long-term. Expression profiles of several proteins were compared to non-transfected H9C2 cells (H9C2) using RT-qPCR, proteomics-based analysis, or Western blotting. GLUT4 surface analysis, glucose uptake, and cell morphology changes as well as apoptosis/necrosis measurements were performed using flow cytometry. Additionally, brain natriuretic peptide (BNP) levels, reactive oxygen species (ROS) formation, glucose consumption, and lactate production were quantified. Long-term hyperglycaemia in H9C2KE2 cells induced increased GLUT4 presence on the cell surface and was associated with exaggerated glucose influx and lactate production. On the metabolic level, hyperglycaemia affected the tricarboxylic acid (TCA) cycle with accumulation of fumarate. This was associated with increased BNP-levels, oxidative stress, and lower antioxidant response, resulting in pronounced apoptosis and necrosis. Chronic glucose overload in cardiomyoblasts induced by GLUT4 overexpression and hyperglycaemia resulted in metabolically stimulated proteome profile changes and metabolic alterations on the TCA level.


  • Open Access

    Dicarbonyl Stress in Diabetic Vascular Disease

    by Bernd Stratmann

    Late vascular complications play a prominent role in the diabetes-induced increase in morbidity and mortality. Diabetes mellitus is recognised as a risk factor driving atherosclerosis and cardiovascular mortality; even after the normalisation of blood glucose concentration, the event risk is amplified—an effect called “glycolytic memory”. The hallmark of this glycolytic memory and diabetic pathology are advanced glycation end products (AGEs) and reactive glucose metabolites such as methylglyoxal (MGO), a highly reactive dicarbonyl compound derived mainly from glycolysis. MGO and AGEs have an impact on vascular and organ structure and function, contributing to organ damage. As MGO is not only associated with hyperglycaemia in diabetes but also with other risk factors for diabetic vascular complications such as obesity, dyslipidaemia and hypertension, MGO is identified as a major player in the development of vascular complications in diabetes both on micro- as well as macrovascular level. In diabetes mellitus, the detoxifying system for MGO, the glyoxalase system, is diminished, accounting for the increased MGO concentration and glycotoxic load. This overview will summarise current knowledge on the effect of MGO and AGEs on vascular function.


  • Open Access

    Enhanced growth factor expression in chronic diabetic wounds treated by cold atmospheric plasma

    by Jonas Hiller, Bernd Stratmann, Jürgen Timm, Tania‐Cristina Costea, Diethelm Tschoepe

    Aims: Cold atmospheric plasma (CAP) has been proven to enhance wound healing in superficial, chronically infected, diabetic foot ulcers. We aimed to investigate the molecular drivers responsible for this macroscopically observed improvement in diabetic wound healing.Methods: Wound exudate was available from each change of dressing within a prospective, randomised, patient‐blinded clinical trial. Specific protein level analyses were conducted via multiplex ELISA for wound samples of a representative subcohort (placebo: n = 13; CAP: n = 14). Expression of fibroblast growth factor 2 (FGF‐2), vascular endothelial growth factor A (VEGF‐A), cytokines and matrix metalloproteinases (MMPs) were evaluated over a treatment period of about 14 days.Results: Analysis revealed increased levels of the growth factors FGF‐2 (placebo: median 46.9 range [32.0–168.6] AU vs. CAP: 113.7[55.8–208.1] AU) and VEGF‐A (placebo: 79.7 [52.4–162.7] AU vs. CAP: 120.8 [51.1–198.1] AU) throughout the treatment period and in head‐to‐head comparison in a daily assessment. CAP‐treated wounds showed increased levels of tumour necrosis factor‐alpha, interleukins 1α and 8. However, the total protein amounts were not significantly elevated. The total protein amounts of MMPs were not altered by CAP.Conclusions: Induction of crucial growth factors, like FGF‐2 and VEGF‐A, and interleukins appears to be an important component of CAP‐mediated promotion of granulation, vascularisation and reepithelialisation in the diabetic foot. These findings demonstrate for the first time that CAP‐mediated growth factor induction also occurs in persons with diabetes, as previously described only in several in vitro and rodent experiments.Clinical Trial registration KPWTRIAL: NCT04205942, ClinicalTrials.gov.


  • Kardiovaskuläre Risiken in der 4.–6. Lebensdekade mit Diabetes mellitus Typ 1

    by Young Hee Lee-Barkey, Bernd Stratmann, Diethelm Tschöpe

  • Plasma Treatment of the Diabetic Foot Syndrome

    by Bernd Stratmann, Tania-Cristina Costea, Diethelm Tschoepe